Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,612.00
Bid: 1,613.00
Ask: 1,614.00
Change: 12.00 (0.75%)
Spread: 1.00 (0.062%)
Open: 1,608.00
High: 1,619.00
Low: 1,604.50
Prev. Close: 1,600.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 keeps head above water as pound sinks

Fri, 19th Aug 2022 17:07

(Alliance News) - The FTSE 100 managed to outperform European counterparts on Friday due to weakness in the pound as consumer confidence in the UK fell to a record low, while attention turns to next week's Jackson Hole Symposium.

The FTSE 100 index closed up 8.52 points, or 0.1%, at 7,550.37, ending the week 0.7% higher.

The FTSE 250 ended down 248.86 points, or 1.2%, at 19,887.79, shedding 2.2% over the course of the week. The mid-cap index is widely considered a more accurate barometer of the UK's economic health due to its domestic exposure.

The AIM All-Share finished down 4.39 points, or 0.5%, at 920.17, losing 1.4% since the start of the week.

The Cboe UK 100 ended up 0.3% at 753.50, the Cboe UK 250 closed down 1.3% at 17,194.58, and the Cboe Small Companies ended down 0.2% at 14,319.05.

In European equities, the CAC 40 stock index in Paris ended down 0.9%, while the DAX 40 in Frankfurt finished 1.1% lower.

"European equities have been hit hard today, as markets start to show signs of a potential impending bearish reversal coming into play. Fortunately for UK investors, the FTSE 100 has managed to perch itself on an island of green, with a collapse in the pound helping to avoid the seemingly inevitable drop into the surrounding red sea. The resurgence in the dollar seen this week serves to highlight the growing feeling that we are on the cusp of another slump, as investors prepare to head for the exit doors once again," said IG Group's Josh Mahony.

In the FTSE 100, drugmakers AstraZeneca and GSK closed up 2.1% and 1.7% respectively.

"The FTSE 100 is outperforming largely due to the weakness of the pound which is helping the big US dollar earners on the index, as well as a strong showing from the more defensive areas of the index, notably health care and GSK and AstraZeneca," explained CMC Markets analyst Michael Hewson.

In the FTSE 250, easyJet lost 6.3% after the budget airline's Spanish pilots began a new three-day work stoppage calling for the reinstatement of conditions they enjoyed before the pandemic, union officials said.

International Consolidated Airlines Group, which owns the flag carrier airline of Spain Iberia, ended the worst blue-chip performer, down 5.1%. Cabin crew at Iberia Express, the low-cost arm of Spain's Iberia national carrier, are also expected to stage a 10-day strike from August 28 to September 6, the USO union has said.

Elsewhere, Cineworld plunged 58% after the Wall Street Journal reported that the movie theatre operator is preparing to declare bankruptcy, as it struggles to recover from pandemic lows.

According to people familiar with the matter, the London-based cinema chain has engaged with lawyers from Kirkland & Ellis LLP and consultants from AlixPartners to advise Cineworld on its bankruptcy process.

Cineworld is expected to fill a chapter 11 petition in the US, and is also considering filing for an insolvency proceeding in the UK.

On Wednesday, Cineworld warned that lacklustre trading was prompting potential financing decisions that could significantly dilute shareholders.

The dollar was higher across the board. The pound was quoted at USD1.1790 at the London equities close, down sharply from USD1.2000 at the close Thursday.

Sterling was dealt a blow after UK consumer confidence hit a record low amid "acute concerns" in the face of the soaring cost of living and bleak economic prospects.

GfK's long-running Consumer Confidence Index fell three points in August to minus 44, its lowest figure since records began in 1974. All five measures that make up the index fell last month, including confidence in personal finances and the general economy.

Confidence in the general economy looking back over the previous year has decreased for eight months in a row to reach minus 68 - some 26 points lower than last August.

The euro stood at USD1.0035 at the European equities close, down from USD1.0132. Against the yen, the dollar was trading at JPY137.15, up sharply from JPY135.10.

Stocks in New York were firmly lower at the London equities close with the US Federal Reserve set to continue on its aggressive rate hike path at its next meeting in September.

Federal Reserve Bank of St. Louis President James Bullard told the Wall Street Journal on Thursday he is considering support for another 75 basis points rate rise at the Fed's policy meeting next month.

Elsewhere, Minneapolis Fed President Neel Kashkari on Thursday said he was insistent that the Fed needed to do more on inflation urgently, even if it meant tipping the economy to the brink of risking a recession.

Meanwhile, US Federal Reserve Chair Jerome Powell will address the who's who of the central banking world in Jackson Hole, Wyoming, on August 26.

The DJIA was down 0.8%, the S&P 500 index down 1.2% and the Nasdaq Composite down 1.9%.

On Wall Street, General Motors was up 2.5% after the automaker said it would reinstate its investor dividend in September and resume "opportunist" share repurchases. GM had suspended payouts at the onset of the pandemic.

Apple was down 1.5% after the tech giant warned of a flaw that is allowing hackers to seize control of iPhones, iPads and Mac computers, and is urging users to install emergency software updates.

Patches were released Thursday and Wednesday by the tech titan to fix what it described as a vulnerability hackers already knew about and may be taking advantage of. However, Apple did not disclose whether it had information regarding the extent to which the issue has been exploited.

"Apple is aware of a report that this issue may have been actively exploited," the Cupertino, California-based company said.

Brent oil was quoted at USD96.45 a barrel at the London stock market close, firm from USD96.12 at the close Thursday.

Gold stood at USD1,748.05 an ounce at the London equities close, lower against USD1,761.70 late Thursday.

The economic events calendar on Monday has the China PBoC loan prime rate announcement overnight.

The UK corporate calendar on Monday has annual results from eConveyancer comparison platform owner Smoove.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.